等待开盘 06-26 09:30:00 美东时间
+2.430
+2.82%
On May 29, 2026, the Company entered into the First Amendment to Amended and Restated License Agreement (the "Amendment"), amending the Amended and Restated License Agreement dated as of February 24, 2025 (as amended,
06-02 04:11
Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 76.7% to $0.18 du...
04-13 20:05
Spyre Therapeutics (NASDAQ:SYRE) announced its Q4 earnings on Thursday, Februar...
02-20 05:32
Top Wall Street analysts changed their outlook on these top names. For a comple...
2025-12-01 22:01
根据美国证券交易委员会(SEC)披露,全球另类资产管理巨头凯雷(CARLYLE GROUP INC)递交了截止至2025年3月31日的第一季度持仓报告(13F...
2025-05-16 17:23
06:24 AM EDT, 09/04/2024 (MT Newswires) -- Spyre Therapeutics (SYRE) has an average buy rating and a price target range of $40 to $54, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia a...
2024-09-04 18:24